NexImmune, Inc. NEXI
At closeNov 10, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 139
- EPS (ttm)
- -18.50
- Shares out
- 1.37M
- Forward P/E
- -0.30
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 100
- Avg volume
- 37
- Open
- 0.0002
- Previous close
- 0.0001
- Day's range
- 0.0002 – 0.0002
- 52-week range
- 0.0001 – 0.0003
- Beta
- 1.93
- Analysts
- Buy
- Earnings date
- Dec 27, 2024
Key statistics
- Enterprise value
- -2.92M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.96M
- Total cash
- 4.45M
- Total debt
- 0
- Return on equity
- -196.47%
- Short % of float
- 1.30%
- 50-day average
- 2.33
- 200-day average
- 4.40
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 27, 2024
Expected Dec 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 27, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -1.69 | — | — |
| May 20, 2024 | Mar 1, 2024 | 0.00 | -2.21 | — | — |
| Apr 16, 2024 | Dec 1, 2023 | 0.00 | -4.99 | — | — |
| Nov 17, 2023 | Sep 1, 2023 | 0.00 | -9.40 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -7.25 | -7.25 | 0.00 | 0.00% |
About NexImmune, Inc.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- neximmune.com
News
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Thursday's Intraday Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session 
12 Health Care Stocks Moving In Monday's Intraday Session 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Friday's Intraday Session - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Your note
Sign in to keep a note on NEXI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARER SOL J | Director | Purchase | Mar 29, 2023 | 4,102,400 |
| BERTRAM TIMOTHY A | Director | Conversion of Exercise of derivative security | Feb 16, 2021 | 78,199 |
| CARMER SCOTT | Chief Executive Officer | Conversion of Exercise of derivative security | Feb 16, 2021 | 7,058 |
| D'ANGIO PAUL | Director | Conversion of Exercise of derivative security | Feb 16, 2021 | 27,847 |
| JONES KRISTI VAUGHAN | Chief Executive Officer | Stock Award(Grant) | Nov 24, 2022 | 369,778 |
| OELKE MATHIAS | Officer | Stock Award(Grant) | Nov 21, 2022 | 134,023 |